Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Impinj Inc (PI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Impinj Inc — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while Impinj Inc trades at $189.45 (market cap $5.60B). The key difference: Kymera Therapeutics Inc. Common Stock is the larger of the two by market cap, and Kymera Therapeutics Inc. Common Stock is more actively traded (779,107 versus 39,355). Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Impinj Inc for 22 Days on average.
| KYMR | PI | |
|---|---|---|
Market Cap | $8.87B | $5.60B |
Volume | 779,107 | 39,355 |
Sector | Health | Technology |
52-Week High | $127.31 | $241.91 |
52-Week Low | $55.80 | $91.34 |
Typical Hold Time | 0 Days | 22 Days |
Enterprise Value | $8.26B | $5.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Impinj (PI) trades at $183.26, down 3.56% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 results with EPS of $0.86 beating estimates, though it operates at a net loss margin of -7.26%. Recent news highlights CEO optimism about growth in RFID tracking markets and upcoming Q3 earnings.
Outlook remains mixed: analyst consensus is bullish (73% buy ratings) with a $178.83 price target, but high valuation multiples and persistent losses pose risks. Key catalysts include Q3 earnings and execution in retail and logistics segments, while competition and margin pressure are concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →
